So what: "No reason" might be a bit misleading. All three companies make drugs, and 2016 has not been a good year to be a biotech company (yes, less than two weeks into the year). The iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) is off more than 14% this year, including a 5.4% drop today.
It's ugly out there, Fools.
Now what: There's really no telling when the bloodbath is going to end, but the good news is that there's no reason to believe the companies are truly worth less now than they were yesterday. BioMarin Pharmaceuticals, Ionis Pharmaceuticals, and ImmunoGen still have the same drugs in their pipeline; in Ionis' case, there are 38 drugs! If those drugs pass their phase 3 trials and get approved, the value of the companies will increase. In BioMarin Pharmaceuticals' case it even has drugs on the market that could drive the value higher with increasing sales.
So why are investors selling? Most likely it's just sector rotation. Investors' risk tolerance changes over time. When they're fearful, they'll sell assets like biotechs that are perceived as more risky.
And you know what Warren Buffett says about times when people are fearful.
Brian Orelli has no position in any stocks mentioned. The Motley Fool recommends BioMarin Pharmaceutical, ImmunoGen, and Ionis Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
Why This Gene Therapy Pioneer Crashed 29.8% in December
Progress toward commercializing its first gene therapy failed to overcome concern about competition last month.
5 Biotech Buyout Candidates for 2018
The Republican-inspired U.S. tax reform could spur an acquisition bonanza in biotech next year. Here's a look at five companies that might be prime targets.
BioMarin Pharmaceutical Inc. on Target for Its 15% Revenue Growth Goal
The biotech keeps plugging along.